These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37199300)

  • 1. Immunotherapy and Targeted Therapy in the Management of Oral Cancers.
    Dutta S; Singhal S; Shah RB; Haque M
    Crit Rev Oncog; 2022; 27(4):23-37. PubMed ID: 37199300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunotherapy in urological cancers.
    Bosnali E; Akdas EM; Telli E; Teke K; Kara O
    Arch Ital Urol Androl; 2024 May; 96(2):12307. PubMed ID: 38818794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
    Boussageon M; Swalduz A; Chouaïd C; Bylicki O
    BioDrugs; 2022 Mar; 36(2):137-151. PubMed ID: 35147894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Zhang J; Medeiros LJ; Young KH
    Front Oncol; 2018; 8():351. PubMed ID: 30250823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Cancer Therapy.
    Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
    Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.
    Matusz-Fisher A; Tan AR
    Expert Opin Biol Ther; 2022 Mar; 22(3):385-395. PubMed ID: 34806498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
    Bhatia A; Burtness B
    Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
    Moreira J; Tobias A; O'Brien MP; Agulnik M
    Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
    Gwynn ME; DeRemer DL
    Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.